Search Results - A. Perrot

Refine Results
  1. 1

    Toward a multivariate formulation of the parametric Kalman filter assimilation: application to a simplified chemical transport model by A. Perrot, O. Pannekoucke, O. Pannekoucke, O. Pannekoucke, V. Guidard

    Published in Nonlinear Processes in Geophysics (2023-06-01)
    Get full text
    Article


  2. 2

    Real-time vision-based control of industrial manipulators for layer-width setting in concrete 3D printing applications by E. Shojaei Barjuei, E. Courteille, D. Rangeard, F. Marie, A. Perrot

    Get full text
    Article


  3. 3

    Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another by L. Filliatre-Clement, H. Busby-Venner, C. Moulin, G. Roth-Guepin, A. Perrot

    Published in Case Reports in Hematology (2017-01-01)
    Get full text
    Article


  4. 4

    Two Rare Complications in One Patient: Acquired von Willebrand Syndrome Associated with Intracranial Plasmacytoma by H. Auge, C. Yguel, E. Schmitt, B. Frotscher, H. Busby-Venner, R. Morizot, C. Moulin, P. Feugier, A. Perrot, L. Filliatre-Clement

    Published in Case Reports in Hematology (2019-01-01)
    Get full text
    Article


  5. 5

    PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by M. V. Mateos, N. Bahlis, L. Costa, A. Perrot, L. Pei, M. Rubin, K. Lantz, W. Sun, M. Jaffe, R. Kobos, A. Nooka

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  6. 6

    P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALITEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY... by A. Perrot, M. Kortüm, R. Popat, K. Uttervall, M.V. Mateos, K. Weisel, K. Van Nimwegen, J. Diels, F. Ong, R. Morano, E. Rubio-Azpeitia, P. Moreau

    Published in Haematologica (2026-04-01)
    Get full text
    Article


  7. 7

    P10 AN ULTRA-SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M-PROTEIN IN PERIPHERAL BLOOD (M-INSIGHT) by V. Bonifay, V. Vimard, S. Noori, C. Wijnands, C. Touzeau, J. Corre, A. Perrot, P. Moreau, H. Caillon, T. Dejoie, T. Luider, M. VanDuijn, J. Jacobs, A. Van Gool, P. Sonigo

    Published in HemaSphere (2023-05-01)
    Get full text
    Article


  8. 8

    B04 IMPLEMENTING M-PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA PATIENTS USING ULTRA-SENSITIVE TARGETED MASS SPECTROMETRY DATA AND AN OFF-THE-SHELF CALIBRATOR by C. Wijnands, P. Langerhorst, S. Noori, J. Gloerich, V. Bonifay, C. Touzeau, J. Corre, A. Perrot, P. Moreau, H. Caillon, T. Luider, A. van Gool, T. Dejoie, M. VanDuijn, J. Jacobs

    Published in HemaSphere (2023-05-01)
    Get full text
    Article


  9. 9

    P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 A... by O. Decaux, C. Hulin, A. Perrot, M. Macro, L. Frenzel, J. Diels, N. J. Perualila, F. Ghilotti, B. Haefliger, E. Goldsztajn, S. Vernet, J. Thevenon, M. Willaime, N. Texier, J. M. Schecter, D. Madduri, C. Jackson, S. Valluri, P. Moreau

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  10. 10

    S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS by C. Touzeau, A. Krishnan, P. Moreau, A. Perrot, S. Z. Usmani, S. Manier, M. Cavo, C. Martinez-Chamorro, A. Nooka, T. Martin, L. Karlin, X. Leleu, N. Bahlis, B. Besemer, L. Pei, R. Verona, S. Girgis, C. Uhlar, R. Kobos, A. Garfall

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  11. 11

    P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T... by T. Facon, S. K. Kumar, T. Plesner, P. Moreau, N. Bahlis, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. P. Venner, K. Weisel, J. R. Mace, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, F. Borgsten, S. Z. Usmani

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  12. 12

    P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER by M. Macro, O. Decaux, A. Perrot, B. Royer, M. Chretien, K. Belhadj, M. Mohty, L. Frenzel, X. Leleu, M. Dib, O. Allangba, P. Zunic, I. Botoc, J. Malfuson, P. Moreau, R. Garlantazec, N. Texier, R. Germain, C. Deal, C. Hulin

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  13. 13

    P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY by C. Hulin, M. Macro, A. Perrot, B. Royer, D. Caillot, K. Belhadj, L. Frenzel, R. Benramdane, H. Demarquette, B. Bareau, S. Darre, C. Calmettes, R. Le Calloch, M. Bouketouche, K. Laribi, N. Texier, M. Willaime, C. Deal, P. Moreau, O. Decaux

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  14. 14

    P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRA... by R. Popat, K.M. Kortüm, H. Magen, V. Mykytiv, C. Liberatore, E. Zamagni, M.C. Da Vià, E. Antonioli, M. Hansson, D. Santra, D. Greer, K. Subrt, P. Hu, E. Aeby, N. Francella, N.M. Suñe, A. Perrot, K. Uttervall

    Published in Haematologica (2026-04-01)
    Get full text
    Article


  15. 15

    P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by M. Delforge, P. Moreau, H. Einsele, V. De Stefano, J. Lindsey-Hill, L. Vincent, S. Mangiacavalli, A. Perrot, E. Ocio, S. ten Seldam, E. I. ’. Groen-Damen, M. Semerjian, V. Strulev, J. M. Schecter, T. Roccia, K. S. Gries, T. Nesheiwat, R. Wapenaar, M.-V. Mateos, K. Weisel

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  16. 16

    C002 | SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NDMM: ANALYSIS OF SUSTAINED MINIMA... by E. Antonioli, P. Moreau, P. Sonneveld, H. Einsele, H. Quach, P. Joy Ho, M. Beksac, C. Hulin, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, H. Pei, A. Sitthi-Amorn, R. L. Carson, P. Rodríguez-Otero, M.A. Dimopoulos, M. Boccadoro

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  17. 17

    P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP... by T. Facon, T. Plesner, S. Usmani, S. Kumar, N. Bahlis, C. Hulin, R. Orlowski, H. Nahi, P. Mollee, K. Ramasamy, M. Roussel, A. Jaccard, M. Delforge, L. Karlin, B. Arnulf, A. Chari, H. Pei, N. Gupta, S. Kaila, K. Matt, K. Gries, R. Carson, F. Borgsten, K. Weisel, A. Perrot

    Published in HemaSphere (2023-05-01)
    Get full text
    Article


  18. 18

    P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MY... by P. Sonneveld, Ph. Moreau, H. Einsele, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, H. Pei, A. Sitthi-Amorn, R.L. Carson, P. Rodríguez-Otero, M.A. Dimopoulos, M. Boccadoro

    Published in Haematologica (2026-04-01)
    Get full text
    Article


  19. 19

    P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA... by K. Weisel, S. Kumar, P. Moreau, N. Bahlis, T. Facon, T. Plesner, R. Orlowski, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. Venner, N. Raje, M. Tiab1, M. Macro, L. Frenzel, X. Leleu, H. Pei, M Krevvata, R Carson, F. Borgsten, S. Usmani

    Published in HemaSphere (2023-05-01)
    Get full text
    Article


  20. 20

    P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE by A. Schavgoulidze, A. Perrot, T. Cazaubiel, X. Leleu, S. Manier, L. Buisson, S. Maheo, L. Do Souto Ferreira, R. Lannes, L. Pavageau, C. Hulin, J.-P. Marolleau, L. Voillat, K. Belhadj, M. Divoux, B. Slama, S. Brechignac, M. Macro, A.-M. Stoppa, L. Sanhes, F. Orsini-Piocelle, J. Fontan, M.-L. Chretien, H. Demarquette, M. Mohty, H. Avet-Loiseau, J. Corre

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: